The Phase 3 REGAL topline readout this month is the primary binary catalyst. Positive results would validate GPS as a potential AML therapy and could trigger a BLA filing. Negative results would remove the company's lead pipeline asset.
Drugs in focus
SLS drug pipeline →galinpepimut-S
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 REGAL trial succeeds, the earliest potential regulatory submission (BLA) would follow the topline readout in Q4 2026, with an FDA review timeline of roughly 10-12 months thereafter, putting a potential approval in late 2027 or early 2028 at the earliest.
- Next catalyst
- None dated
What to watchWatch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $7.86entry
- T+1 · yesterday −4.96%α −3.05% · $7.47
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SELLAS reported Q3 2026 net loss of $10.1M ($0.05 per share), in line with the $-0.05 consensus. Cash and equivalents stood at $134.7M. The key catalyst is the upcoming topline readout of the Phase 3 REGAL trial of GPS in AML, expected this month, and preliminary Phase 2 SLS009 data expected in Q4 2026.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $10.1M, or $0.05 per share, vs $6.8M loss ($0.06) in Q3 2025
- Cash and cash equivalents of $134.7M as of September 30, 2026
- 80th event in Phase 3 REGAL trial of GPS occurred in October 2026; topline results expected this month
- 40 of 80 patients enrolled in Phase 2 trial of SLS009 in newly diagnosed AML; preliminary topline data expected Q4 2026
- Phase 2 data for SLS009 in relapsed/refractory AML to be presented at ASH December 2026
Financial Impact
Net loss widened to $10.1M from $6.8M in Q3 2025; R&D spend increased to $7.0M from $4.2M; cash position $134.7M
Risk Factors
- Phase 3 REGAL trial may fail to meet its primary endpoint, eliminating the lead program
- Phase 2 SLS009 data may disappoint, reducing pipeline optionality
- Cash burn rate increased to $10.1M per quarter; $134.7M provides runway but no revenue stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001390478-26-000021 |
| Document: sls-20261112.htm | 0001390478-26-000021 |
| Document: 0001390478-26-000021-index-headers.html | 0001390478-26-000021 |
| Document: 0001390478-26-000021-index.html | 0001390478-26-000021 |
| Document: 0001390478-26-000021.txt | 0001390478-26-000021 |
| 8-K Data (Synthetic) | 0001390478-26-000021 |
Track record
16 reports on SLS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today 424B5 Bearish 6/10 Entry $16.40 Now $19.15 −16.74% settles Feb 17
- Nov 17, 2026today Press Release Bearish 6/10 Entry $18.59 Now $19.15 −3.01% settles Feb 17
- Nov 17, 2026today 8-K Bullish 7/10 Entry $7.75 Now $19.15 +147.10% settles Feb 16
- Nov 17, 2026today Press Release Bullish 8/10 Entry $7.75 Now $19.15 +147.10% settles Feb 16
- Nov 12, 20265d ago 8-K Neutral 5/10 Viewing Entry $7.86 Now $19.15 +143.64% settles Feb 11
- Nov 10, 20267d ago SC 13G Neutral 3/10 Entry $8.37 Now $19.15 +128.79% settles Feb 8
- Nov 3, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.87 Now $19.15 +115.90% settles Feb 1
- Oct 28, 202620d ago Press Release Mixed 7/10 Entry $10.38 Now $19.15 +84.49% settles Jan 26
- Oct 27, 202621d ago SC 13G/A Neutral 3/10 Entry $10.38 Now $19.15 +84.49% settles Jan 26
- Sep 25, 20267w ago Press Release Neutral 3/10 Entry $11.61 Now $19.15 +64.94% settles Dec 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers